크론병에서 인플릭시맵 투약 후 발생한 전신홍반루푸스 1예
Infliximab-Induced Lupus in Crohn’s Disease
최수진, 김소현, 김혜영, 이용준, 황보현, 양석균, 김용길,
소속 상세정보
최수진 ( Choi Su-Jin )
울산대학교 의과대학 서울아산병원 내과
김소현 ( Kim So-Hyun )
울산대학교 의과대학 서울아산병원 내과
김혜영 ( Kim Hye-Yeong )
울산대학교 의과대학 서울아산병원 내과
이용준 ( Lee Yong-June )
울산대학교 의과대학 서울아산병원 내과
황보현 ( Hwangbo Hyun )
울산대학교 의과대학 서울아산병원 내과
양석균 ( Yang Suk-Kyun )
울산대학교 의과대학 서울아산병원 내과
김용길 ( Kim Yong-Gil )
울산대학교 의과대학 서울아산병원 내과
Abstract
Infliximab (IFX) is an anti-tumor necrosis factor (TNF) monoclonal antibody used to treat rheumatoid arthritis, ankylosing spondylitis, and Crohn’s disease. Rarely, anti-TNF-induced lupus (ATIL) may occur. ATIL differs from classical drug-induced lupus. We report a 49-year-old woman who developed polyarthralgia after 2 years of IFX treatment for Crohn’s disease. Based on the autoantibody profiles, ATIL was diagnosed and low-dose glucocorticoid, hydroxychloroquine, and celecoxib were prescribed. However, arthralgia and hemolytic anemia developed. Because the anti-dsDNA titers waxed and waned, she was switched to vedolizumab, a monoclonal antibody to the human lymphocyte α4β7 integrin. Six months after switching treatment, the arthralgia had improved and the anti-dsDNA antibody normalized. Here, we report a case of ATIL that resolved after switching from infliximab to vedolizumab.
키워드
Infliximab; Lupus erythematosus, Systemic; Crohn disease
원문 및 링크아웃 정보
등재저널 정보